Want to see HK:6127 full AI Analyst Report?
JOINN Laboratories (China) Co., Ltd. Class H (6127) AI Stock Analysis
JOINN Laboratories (China) Co., Ltd. Class H
(HKEX:6127)
The score is primarily supported by strong financial stability (very low leverage) and improved TTM profitability. It is held back by weak cash conversion versus net income and clear negative technical momentum, with valuation also elevated given the high P/E and low dividend yield.
JOINN Laboratories (China) Co., Ltd. Class H (6127) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 31.33B
- Dividend Yield
- 0.60%
- Average Volume (3M)
- 5.46M
- Price to Earnings (P/E)
- 29.1
- Beta (1Y)
- 1.24
- Revenue Growth
- 16.68%
- EPS Growth
- 442.43%
- Country
- Hong Kong
- Employees
- 2,649
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Diagnostics & Research
JOINN Laboratories (China) Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Joinn Laboratories (China) Co., Ltd. is a global provider of essential preclinical and non-clinical research services, operating across the United States, mainland China, and various international markets. The company organizes its operations into th...
JOINN Laboratories (China) Co., Ltd. Class H Financial Statement Overview
Summary
Financials are supported by a very strong, low-leverage balance sheet and a sharp TTM profitability rebound (high net margin and solid EBIT/EBITDA margins). Offsetting this, revenue and margins have been volatile across recent years and cash conversion is weak (operating cash flow is only about half of net income), which raises questions about earnings quality and durability.
Income Statement
72PositiveBalance Sheet
88Very PositiveCash Flow
63Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.86B | 1.66B | 2.02B | 2.38B | 2.27B | 1.52B |
| Gross Profit | 447.63M | 343.31M | 573.77M | 1.01B | 1.09B | 739.12M |
| EBITDA | 609.39M | 483.24M | 234.36M | 639.52M | 1.36B | 738.86M |
| Net Income | 1.14B | 297.84M | 74.08M | 396.99M | 1.07B | 557.46M |
Balance Sheet | ||||||
| Total Assets | 11.34B | 9.68B | 9.40B | 10.03B | 10.36B | 8.54B |
| Cash, Cash Equivalents and Short-Term Investments | 2.54B | 2.63B | 2.36B | 4.77B | 3.33B | 4.84B |
| Total Debt | 37.07M | 1.42M | 21.60M | 41.92M | 87.71M | 95.32M |
| Total Liabilities | 2.18B | 1.36B | 1.32B | 1.75B | 2.17B | 1.39B |
| Stockholders Equity | 9.16B | 8.32B | 8.08B | 8.28B | 8.18B | 7.14B |
Cash Flow | ||||||
| Free Cash Flow | 609.38M | 300.96M | 69.54M | 430.15M | 696.23M | 448.41M |
| Operating Cash Flow | 1.07B | 444.57M | 338.93M | 622.88M | 971.07M | 685.66M |
| Investing Cash Flow | -1.35B | -419.19M | -1.96B | -315.43M | -2.16B | -2.07B |
| Financing Cash Flow | -62.95M | -66.98M | -265.63M | -361.68M | -99.33M | 5.29B |
JOINN Laboratories (China) Co., Ltd. Class H Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6127, the sentiment is Negative. The current price of 22.88 is below the 20-day moving average (MA) of 27.12, below the 50-day MA of 25.63, and above the 200-day MA of 22.26, indicating a neutral trend. The MACD of -0.99 indicates Positive momentum. The RSI at 38.80 is Neutral, neither overbought nor oversold. The STOCH value of 17.99 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:6127.
JOINN Laboratories (China) Co., Ltd. Class H Peers Comparison
Overall Rating
HK:235975Outperform
HK:154871Outperform- HK:612760Neutral
HK:334755Neutral
HK:682154Neutral
HK:375953Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:2359 | 75Outperform | HKD 506.60B | 15.47 | 30.77% | 1.29% | 38.26% | 84.56% |
| HK:1548 | 71Outperform | HKD 79.58B | -14.95 | -16.23% | ― | 53.48% | -120.02% |
| HK:6127 | 60Neutral | HKD 36.16B | 29.06 | 13.10% | 0.60% | 16.68% | 442.43% |
| HK:3347 | 55Neutral | HKD 42.54B | -76.42 | -2.00% | 0.38% | 21.72% | -169.67% |
| HK:6821 | 54Neutral | HKD 54.78B | 40.79 | 6.66% | 1.44% | 23.95% | 18.73% |
| HK:3759 | 53Neutral | HKD 80.45B | 41.79 | 10.93% | 0.85% | 24.21% | 19.72% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:6127 | JOINN Laboratories (China) Co., Ltd. Class H | 22.88 | 2.30 | 11.20% | |
| HK:1548 | Genscript Biotech Corporation | 35.02 | 17.98 | 105.52% | |
| HK:3347 | Hangzhou Tigermed Consulting Co., Ltd. Class H | 37.92 | -8.52 | -18.35% | |
| HK:3759 | Pharmaron Beijing Co., Ltd. Class H | 26.98 | 1.65 | 6.50% | |
| HK:2359 | WuXi AppTec Co., Ltd. Class H | 185.40 | 83.35 | 81.67% | |
| HK:6821 | Asymchem Laboratories (Tianjin) Co., Ltd. Class H | 103.90 | 19.42 | 22.99% |
JOINN Laboratories (China) Co., Ltd. Class H Corporate Events
JOINN Laboratories posts surging profits and revenues in Q3 2026
JOINN Laboratories (China) Co., Ltd. reported a strong third-quarter 2026 performance, with revenue for the period reaching RMB 484.1 million, up 53.0% year-on-year, and year-to-date revenue rising 20.6% to RMB 1.19 billion. Net profit attributable t...
JOINN Laboratories revamps company secretarial, representative and process agent roles
JOINN Laboratories (China) Co., Ltd. announced a reshuffle of its corporate governance roles, with joint company secretary and authorised representative Ms. Lee Ching Ying resigning, and process agent responsibilities for Ms. Lee and Ms. Ho Wing Tsz...
JOINN Laboratories Schedules Board Meeting to Approve Third-Quarter Results
JOINN Laboratories (China) Co., Ltd., a Hong Kong-listed PRC joint stock company in the laboratory and research services industry, is governed by a board that includes executive, non-executive, independent non-executive, and employee directors. The c...
JOINN Labs commits RMB540 million to CITIC Securities products in discloseable deal
JOINN Laboratories (China) Co., Ltd. disclosed that a group subsidiary has subscribed to a series of CITIC Securities financial products between 20 April 2026 and 23 September 2026. The aggregate outstanding investment in these seven structured produ...
JOINN Labs interim profit soars on fair value gains despite modest revenue growth
JOINN Laboratories (China) Co., Ltd. reported a modest 5.3% year-on-year rise in revenue to RMB703.8 million for the six months ended 30 June 2026, but delivered a sharply higher gross profit of RMB144.9 million as cost of services fell slightly. The...
JOINN Laboratories Renews De Minimis Connected Leases for Key Beijing Facilities
JOINN Laboratories (China) Co., Ltd. has renewed leasing arrangements for key facilities in Beijing’s Daxing District, signing three-year leases from 1 September 2026 to 31 August 2029 with the Beijing Joinn Biologics Group for properties used...
JOINN Laboratories sets August board meeting to approve interim results
JOINN Laboratories (China) Co., Ltd. has scheduled a board meeting for 28 August 2026 to review and approve the Group’s interim results for the six months ended 30 June 2026. The session may also address other corporate matters, signaling an up...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 29, 2026